A Review of Waters'' Bonded-Phase Shield Technology and Its Use in High Performance Liquid Chromatography (HPLC)

Library Number:
WA00405
Part Number:
WA00405
Author(s):
John O''Gara
Source:
Waters Whitepaper
Content Type:
Literature
Content Subtype:
White Papers
Compounds:
Toluamide; Chlorpheniramine maleate;Uracil; Propranolol; Butyl paraben; Dipropylphthalate; Naphthalene; Amitriptyline; Acenaphthene; Suprofen; Ketoprofen; Naproxen; Tolmetin; Fenoprofen; Diclofenac; Indomethacin; Ibuprofen; Furazolidone & impurities; Substituted benzenes: benzyl alcohol; benzamide; aniline; phenol; salicylic acid; 2-methylaniline; benzaldehyde; benzonitrile; benzoic acid; methylbenzoate; 2-methylbenzamide
Column:
SymmetryShield(™) RP8; RP18 N/A Columns N/A N/A XTerra RP18; RP8 N/A Columns N/A N/A
Shield bonded phases have been introduced to HPLC over the past 10 years. These phases represent a major departure from traditional reliance on 30-year-old silane and bonding technology. Application of second generation one-step synthesis methodologies afford a well-rounded column for any reversed-phase separation. In comparison to their purely alkyl counterparts, shield phases provide the end user with three significant benefits: -- 1) improved peak shape for basic analytes; -- 2) unique selectivity, and -- 3) stable retention in highly aqueous mobile phases. Significant progress has been made into understanding the mechanism of this novel class of RP materials. More insight is expected as these materials become increasingly utilized to solve difficult separation problems.

Title Format File Size
000207en PDF 100.67kB